Nurix Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nurix Therapeutics generated cash of -$81,365,000, which is more than the previous year. Cash used in financing activities reached the amount of $3,217,000 last year. Net change in cash is therefore -$9,847,000.
Cash Flow
| 2018 | -31.67M | 39.99M | 529K |
|---|---|---|---|
| 2019 | 601K | 8.49M | 126K |
| 2020 | -80K | -254.40M | 339.02M |
| 2021 | -84.36M | -108.25M | 153.88M |
| 2022 | -159.80M | 27.19M | 117.19M |
| 2023 | -81.36M | 68.30M | 3.21M |
NRIX Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 65.37M | 80.79M | 119.52M | 34.98M | 25.76M | 16.91M |
Operating activities | ||||||
Net income | -143.94M | -180.36M | -117.19M | -43.24M | -21.69M | -9.42M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 13.65M | 10.80M | 6.08M | 2.18M | 2.35M | 2.98M |
Stock-based compensation expense | 33.67M | 28.13M | 15.8M | 4.30M | 510K | 0 |
| Deferred income tax benefit | 33.67M | 28.13M | 15.8M | 4.30M | 510K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 6M | -6M | -11.34M | 0 | 0 |
Inventories | 0 | 0 | 6.77M | 11.34M | 0 | 0 |
Accounts payable | 1.61M | 85K | 1.58M | 1.23M | 302K | -519K |
Cash generated by operating activities | -81.36M | -159.80M | -84.36M | -80K | 601K | -31.67M |
Investing activities | ||||||
Purchases Of Investments | -246.33M | -239.36M | -348.49M | -275.22M | -9.35M | -12.91M |
Investments In Property Plant And Equipment | -8.40M | -12.24M | -5.66M | -4.55M | -1.65M | -1.59M |
Acquisitions Net | 0 | -39.44M | 102.59M | 249.85M | -10.14M | 0 |
Cash generated by investing activities | 68.30M | 27.19M | -108.25M | -254.40M | 8.49M | 39.99M |
Financing activities | ||||||
Common Stock Issued | 3.21M | 19.4M | 150.15M | 339.03M | 142K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1K | -7K | -16K | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 3.21M | 117.19M | 153.88M | 339.02M | 126K | 529K |
Net Change In Cash | -9.84M | -15.41M | -38.73M | 84.54M | 9.22M | 8.84M |
Cash at end of period | 55.52M | 65.37M | 80.79M | 119.52M | 34.98M | 25.76M |
| Data source | Data source | Data source | Data source |